Benzodiazepine-GABAA receptor complex ligands in two models of anxiety

Journal of Neural Transmission
M NazarA Płaźnik

Abstract

In the present study, the actions of several compounds with different intrinsic activities and BDZ receptor selectivity were examined in two well established animal models of anxiety: the open field test (OFT) and Vogel's punished drinking text (VT). Full agonists at the BDZ GABAA receptor (midazolam and diazepam) showed anxiolytic-like effects in both tests; however, the doses necessary to disinhibit animal behavior controlled by fear were higher in the VT than in the OFT. None of the partial BDZ receptor agonists studied (bretazenil, Ro 19-8022 and abecarnil) diminished neophobia-like behavior of rats in the OFT, and their sedative influence on gross behavior prevailed. On the other hand, all three drugs produced a clear-cut anxiolytic effect in the VT. A selective BDZ, receptor subtype full agonist (zolpidem) had a similar profile of action to that of partial agonists with an even stronger sedative effect in the OFT. Alpidem (a selective BDZ1 receptor partial agonist) did not reveal any anxiolytic action in either test. Flumazenil (an antagonist at the BDZ-GABAA receptors) also produced no effect in the OFT, or the VT. An inverse BDZ receptor agonist, beta-carboline-3-carboxylate methyl ester (beta-CCM), evoked an anxiogenic...Continue Reading

References

Jan 1, 1990·Pharmacology & Therapeutics·G T Pollard, J L Howard
May 1, 1990·Pharmacopsychiatry·B ZivkovicK G Lloyd
Mar 1, 1995·Journal of Psychiatric Research·H Lüddens, E R Korpi
Sep 1, 1994·Pharmacology, Biochemistry, and Behavior·M F DaviesG H Loew
Dec 1, 1994·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·A PlaznikM Jessa
Jun 23, 1994·European Journal of Pharmacology·M SerraG Biggio
Jan 1, 1996·Pharmacology, Biochemistry, and Behavior·S W ChenG H Loew
Mar 1, 1996·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·M JessaA Plaznik

❮ Previous
Next ❯

Citations

Jun 26, 2012·Psychopharmacology·Karina A ZaninRoberto Frussa-Filho
Dec 24, 2005·Journal of Neural Transmission·A Wisłowska-StanekA Płaźnik
Jul 31, 2013·Neuropharmacology·Sairam KrishnamurthyKeerikkattil P Joy
Feb 26, 2003·European Journal of Pharmacology·Laetitia Prut, Catherine Belzung
Jan 26, 2002·Behavioural Brain Research·André RamosReinaldo N Takahashi
Aug 21, 2003·Progress in Neurobiology·Mark J Millan
Sep 16, 2009·Evidence-based Complementary and Alternative Medicine : ECAM·Paolo BellaviteAnita Conforti
Dec 17, 2004·Journal of Clinical Pharmacology·Carl FulwilerSapna Kalsy
Aug 10, 2010·Expert Review of Neurotherapeutics·Fernanda Corrêa CoutinhoAntonio Egidio Nardi
Jun 2, 2009·International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience·Sònia Darbra, Marc Pallarès
Oct 27, 2004·Pharmacology, Biochemistry, and Behavior·Miroslav M SavićDubravko R Bokonjić
Jul 1, 2004·Neuroscience and Biobehavioral Reviews·Julian C LeslieGerard R Dawson
Aug 20, 2011·Pharmacology, Biochemistry, and Behavior·Stephanie M MillerJoseph S Lonstein
Sep 26, 2015·Pharmacological Reviews·Esa R KorpiGavin S Dawe
Jul 17, 2004·The Journal of Pharmacology and Experimental Therapeutics·Alan C FosterKathleen R Gogas
Mar 3, 2004·Annals of the New York Academy of Sciences·Torbjörn BäckströmElisabeth Zingmark
Dec 1, 1998·CNS Drug Reviews·David J Sanger, Henri Depoortere
Sep 6, 2019·Evidence-based Complementary and Alternative Medicine : ECAM·Laura RombolàLuigi Antonio Morrone

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.